Previous close | 150.88 |
Open | 149.80 |
Bid | 0.00 x 800 |
Ask | 0.00 x 900 |
Day's range | 145.36 - 150.36 |
52-week range | 115.03 - 217.25 |
Volume | |
Avg. volume | 3,661,123 |
Market cap | 57.215B |
Beta (5Y monthly) | 1.70 |
PE ratio (TTM) | 7.55 |
EPS (TTM) | 19.64 |
Earnings date | 02 May 2023 - 08 May 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 226.64 |
CRISPR Therapeutics (NASDAQ: CRSP) has a couple of things in common with a company that's made the headlines over the past few years: coronavirus vaccine maker Moderna (NASDAQ: MRNA). Today, CRISPR's market value sits at about $3.4 billion. Since, Moderna has grown to become a $58 billion company, with a blockbuster product and three more potential ones on the horizon.
Moderna (NASDAQ: MRNA) helped some investors make a fortune over the past few years. The stock has climbed more than 400% since March 2020 -- that's when the company's coronavirus vaccine program gained traction. Recently, though, investors have worried about Moderna's post-pandemic revenue, and that's weighed on share performance.
Moderna (MRNA) collaborates with Generation Bio to develop non-viral genetic medicines. For this, it leverages the latter's closed-end DNA (ceDNA) and cell-targeted LNPs (ctLNP) technologies.